NCEL

Company Overview — What Does NLS Pharmaceutics Ltd. Do?

NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland. NLS Pharmaceutics Ltd. (NCEL) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Alexander Zwyer and employs approximately 6 people. With a market capitalization of $11M, NCEL is one of the notable companies in the Healthcare sector.

NLS Pharmaceutics Ltd. (NCEL) Stock Rating — Reduce (April 2026)

As of April 2026, NLS Pharmaceutics Ltd. receives a Reduce rating with a composite score of 33.6/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.NCEL ranks #3,613 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, NLS Pharmaceutics Ltd. ranks #579 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

NCEL Stock Price and 52-Week Range

NLS Pharmaceutics Ltd. (NCEL) currently trades at $2.36. The stock gained $0.27 (12.9%) in the most recent trading session. The 52-week high for NCEL is $6.48, which means the stock is currently trading -63.6% from its annual peak. The 52-week low is $0.74, putting the stock 218.9% above its annual trough. Recent trading volume was 44K shares, suggesting relatively thin trading activity.

Is NCEL Overvalued or Undervalued? — Valuation Analysis

NLS Pharmaceutics Ltd. (NCEL) carries a value factor score of 12/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 6.74x, versus the sector average of 2.75x.

At current multiples, NLS Pharmaceutics Ltd. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

NLS Pharmaceutics Ltd. Profitability — ROE, Margins, and Quality Score

NLS Pharmaceutics Ltd. (NCEL) earns a quality factor score of 21/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -563.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -354.8% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

NCEL Debt, Balance Sheet, and Financial Health

NLS Pharmaceutics Ltd. has a debt-to-equity ratio of 0.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. Total debt on the balance sheet is $0. Cash and equivalents stand at $2M.

NCEL has a beta of -1.28, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for NLS Pharmaceutics Ltd. is 33/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

NLS Pharmaceutics Ltd. Revenue and Earnings History — Quarterly Trend

In TTM 2026, NLS Pharmaceutics Ltd. reported revenue of $0 and earnings per share (EPS) of $-2.63. Net income for the quarter was $-2M. Operating income came in at $-4M.

In FY 2024, NLS Pharmaceutics Ltd. reported revenue of $0 and earnings per share (EPS) of $-2.63. Net income for the quarter was $-2M. Operating income came in at $-4M.

In FY 2023, NLS Pharmaceutics Ltd. reported revenue of $0 and earnings per share (EPS) of $-12.75. Net income for the quarter was $-12M. Operating income came in at $-12M.

In FY 2022, NLS Pharmaceutics Ltd. reported revenue of $0 and earnings per share (EPS) of $-33.52. Net income for the quarter was $-16M. Operating income came in at $-15M.

Over the past 7 quarters, NLS Pharmaceutics Ltd. has experienced revenue contraction from $0 to $0. Investors analyzing NCEL stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

NCEL Dividend Yield and Income Analysis

NLS Pharmaceutics Ltd. (NCEL) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

NCEL Momentum and Technical Analysis Profile

NLS Pharmaceutics Ltd. (NCEL) has a momentum factor score of 55/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 18/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 69/100 reflects moderate short selling activity.

NCEL vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, NLS Pharmaceutics Ltd. (NCEL) ranks #579 out of 838 stocks based on the Blank Capital composite score. This places NCEL in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing NCEL against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full NCEL vs S&P 500 (SPY) comparison to assess how NLS Pharmaceutics Ltd. stacks up against the broader market across all factor dimensions.

NCEL Next Earnings Date

No upcoming earnings date has been announced for NLS Pharmaceutics Ltd. (NCEL) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy NCEL? — Investment Thesis Summary

The quantitative profile for NLS Pharmaceutics Ltd. suggests caution. The quality score of 21/100 flags below-average profitability. The value score of 12/100 indicates premium valuation. High volatility (stability score 33/100) increases portfolio risk.

In summary, NLS Pharmaceutics Ltd. (NCEL) earns a Reduce rating with a composite score of 33.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on NCEL stock.

Related Resources for NCEL Investors

Explore more research and tools: NCEL vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare NCEL head-to-head with peers: NCEL vs AZN, NCEL vs SLGL, NCEL vs VMD.